Paulson AS, et al. - Here, the authors described ramucirumab monotherapy or combination therapy use for the treatment of patients with the gastric or gastroesophageal junction (GEJ) cancer in a community oncology practice setting. Compared to patients who received ramucirumab in combination, those who received ramucirumab monotherapy started ramucirumab therapy later after diagnosis and were found to be older. Survival outcomes obtained from community oncology practices were similar to data from phase 3 clinical trials.